The three direct-acting antiviral combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir (3D regimen) is a combination therapy that was recently approved for the treatment of genotype-1 chronic hepatitis C virus infection.

Potential drug–drug interactions with the 3D regimen were identified by applying pharmacokinetic study data to known routes of metabolism and disposition of more than 200 prescription and over-the-counter drugs.

The majority of concomitant medications assessed are compatible with 3D therapy. Where interaction is possible, guidance on dose adjustment and/or clinical monitoring are provided.